Data as of Apr 17
| +0.26 / +0.78%|
The 5 analysts offering 12-month price forecasts for Enanta Pharmaceuticals Inc have a median target of 45.00, with a high estimate of 50.00 and a low estimate of 41.00. The median estimate represents a +34.77% increase from the last price of 33.39.
The current consensus among 5 polled investment analysts is to Buy stock in Enanta Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.